GTBP · GT Biopharma, Inc. · Exempt Offerings
$6.47
-0.41 (-5.89%)
At close · Sep 30
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year of the date that the financial statements are issued. In addition, the Company's independent registered public accounting firm, in its report on the Company's December 31, 2025 financial statements, raised substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$12.43M
Shares
1.80M
Volume · Sep 30
29.76K
Avg daily vol (16 sessions)
145.1K
Private capital raises reported to the SEC on Form D under Regulation D, showing the offering size, amount sold, minimum investment and number of investors. Public operating companies rarely raise capital this way, so this page is often empty.
| Filed | Type | Industry | Offering | Sold | Exemptions |
|---|---|---|---|---|---|
| 2026-09-29 | New | Biotechnology | $38,958,054 | $7,750,000 | 06b |
| 2025-05-28 | New | Biotechnology | $20,000,000 | $0 | 06b |
| 2025-05-27 | New | Biotechnology | $5,950,000 | $5,950,000 | 06b |
| 2025-03-07 | New | Biotechnology | $1,280,358 | $1,280,358 | 06b |
| 2020-07-23 | Amendment | Biotechnology | Indefinite | $5,607,000 | 06b |
| 2020-06-12 | New | Biotechnology | Indefinite | $2,417,000 | 06b |
Showing 1–6 of 6 filings